Oticon Medical’s Sentio™ System Receives Regulatory Clearance in the US
Oticon Medical announced today the U.S. Food and Drug Administration (FDA) clearance of its first active transcutaneous bone conduction hearing system, the Sentio System. Sentio System delivers the proven benefits of the Ponto™ System – and more – in a transcutaneous option.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240712765107/en/
The Sentio System includes an external Sentio 1 Mini sound processor and a Sentio Ti Implant placed under the skin. (Photo: Business Wire)
The system includes Sentio 1 Mini, an external sound processor, and Sentio Ti Implant, placed under the skin. It is the smallest transcutaneous system available to date1.
While Ponto and other percutaneous bone-anchored hearing systems use skin-protruding abutments, the Sentio System provides an alternative keeping the skin intact. The Sentio System offers an additional solution for patients and supports our commitment to "freedom of choice."
“With the launch of Sentio System, we provide best-in-class and the smallest active transcutaneous system. More importantly, Oticon Medical now offers a complete portfolio of bone-anchored hearing systems. This portfolio meets the needs of patients and customers, and fits diverse clinical settings and global reimbursement schemes for the treatment. We strongly believe that offering a broad portfolio is the path to achieving our mission to "Help more people" and give more potential users the quality of life improvements these systems offer”, says René Govaerts, President & General Manager, Oticon Medical.
The Sentio 1 Mini is designed with a focus on user comfort and ease of use. The device's design and slim profile make it 26% lighter than an alternative1. It gives access to a 360-degree sound experience and offers the widest bandwidth of 9.5kHz.
Sentio Ti is a SuperPowerful implant developed to support patient’s progressive hearing loss, without the need for additional surgeries. Sentio Ti is designed and verified for a higher maximum force output, so that patients can rely on its ability to handle more powerful sound processors2. From a surgeon’s perspective, the implant is designed for surgical flexibility, ensuring a straightforward procedure.
Sentio System is indicated for candidates aged 12 and older who have been diagnosed with conductive hearing loss, mixed hearing loss, or single-sided deafness.
This launch marks a significant milestone for Oticon Medical, as it continues to deliver the innovative hearing solutions that help people live life to the fullest.
For more information visit www.oticonmedical.com.
Not all products are available in all markets. Product availability and indications are subject to regulatory approval and may vary depending on the market.
About Oticon Medical
Oticon Medical is a global company in implantable hearing solutions, dedicated to bringing the power of sound to people at every stage of life. For more than a decade, we have made bone anchored hearing systems more accessible by simplifying the treatment for physicians, audiologists, and patients alike.
We believe that patients and hearing care professionals should be able to choose the best possible solution at any time along the patient journey. We call it “Freedom of Choice” and it has always been paramount to Oticon Medical. This is the reason why our solutions are designed to be compatible whenever possible. As a result, an implant from Oticon Medical stands as a true testament to our unwavering lifelong support.
We work collaboratively with professionals to ensure that every solution we create is designed with our users’ needs in mind. We have a strong passion to provide innovative solutions and support that enhance quality of life and help people live life to the fullest – now and in the future.
Because we know how much sound matters.
References
1 Sentio implant and sound processor physical features and comparison to other devices (Doc-00123204)
2 275144en Product Information Sentio 1 Mini
View source version on businesswire.com: https://www.businesswire.com/news/home/20240712765107/en/
Contacts
Erik Lund
Marketing Director, Oticon Medical
E-mail: erld@oticonmedical.com
Mobile: +46 76 304 4482
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
www.businesswire.com
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Ravio raises $12m Series A to modernise compensation data for global workforces8.5.2025 10:00:00 EEST | Press release
Ravio has raised a $12m Series A funding round led by Spark Capital (US) with participation from Blackbird (Australia) and Cherry Ventures (Europe) to modernise how companies manage compensation with real-time market data and decision making tools. Ravio counts leading consumer brands like Just Eat Takeaway and Octopus Energy among its customers, alongside fintech leaders such as Wise, Adyen, and Mollie. Popular tech names like Zoopla and Skyscanner have also chosen Ravio to set their compensation strategies. The compensation data gap Despite representing 70% of operating costs, most companies make these important decisions using patchy data that's 12-18 months old. This outdated approach creates significant issues: Talent leaves when underpaid compared to current market rates Companies overspend on some roles while struggling to attract talent in others Pay inequities develop as new hires and existing staff operate from different reference points "The idea for Ravio was born from runn
Celonis Recognized as a Leader for Third Consecutive Year in 2025 Gartner® Magic Quadrant™ for Process Mining Platforms8.5.2025 10:00:00 EEST | Press release
Celonis, the global leader in Process Mining and Process Intelligence, today announced that it has been named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third time. Celonis was placed in the Leaders’ Quadrant, being positioned highest on the Ability to Execute axis and furthest on the Completeness of Vision axis once again. “We are honored to be named a Leader in the Gartner Magic Quadrant for Process Mining Platforms for the third year in a row,” said Alex Rinke, co-CEO and co-founder of Celonis. “We believe this recognition is a testament to our pioneering product innovation, our system-agnostic Process Intelligence platform, and our impressive global partner network. This recognition wouldn’t have been possible without the dedication and commitment of our customers, partners and Celonauts. Looking ahead, what excites me most is the huge potential for Celonis to enable our customers to maximize the ROI from their AI investments.” “Celonis gives us a s
Vista Equity Partners Launches VistaOne to Expand Access to Private Software Investments8.5.2025 10:00:00 EEST | Press release
Vista Equity Partners (“Vista”), a global technology investor that specializes in enterprise software, today announced the launch of VistaOne (Lux) (“VistaOne” or the “Fund”), an open-ended investment vehicle that provides eligible non-US individual investors access to Vista’s private equity platform in a single, scaled solution. The software sector has a projected 2027 total addressable market of $59 trillion and a growth rate of approximately 17%, making it the largest and fastest growing in the global economy.1 Yet approximately 96% of software companies are privately held and therefore inaccessible to most individual investors.2 VistaOne is one of the first software-specific evergreen private equity funds available to the private wealth market. Founded in 2000, Vista is an operationally focused investor that pioneered a proprietary and systematic approach to value creation developed and refined over the course of 25 years and 600+ transactions. Enterprise software touches almost ev
Takeda Announces FY2024 Full Year Results and FY2025 Outlook Reflecting Growth & Launch Products Momentum, Strong Cash Flow Generation and Late-Stage Pipeline Progress8.5.2025 09:36:00 EEST | Press release
Takeda (TOKYO:4502/NYSE:TAK) today announced financial results for fiscal year 2024 (period ended March 31, 2025) with continued strong momentum in Growth & Launch Products offsetting loss of exclusivity impact to drive revenue and Core Operating Profit growth, supported by robust cost management. Takeda has built a high-value late-stage pipeline with potentially life-transforming new treatment options for patients. Following a positive Phase 3 readout for rusfertide in Oncology in March 2025, the company anticipates a further two Phase 3 readouts in core therapeutic areas this fiscal year. FY2025 Management Guidance at CER reflects residual carry-over of VYVANSE® generic impact, continued efficiency savings and investment in R&D and launch preparation for Takeda’s late-stage pipeline. Takeda chief executive officer, Christophe Weber, commented: “Takeda delivered excellent results in FY2024. Our return to Core Operating Profit margin growth underscores the strength of our Growth & Laun
AB InBev Reports First Quarter 2025 Results8.5.2025 08:03:00 EEST | Press release
Anheuser-Busch InBev (Brussel:ABI) (BMV:ANB) (JSE:ANH) (NYSE:BUD): This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250507671244/en/ AB InBev Strategic Priorities Regulated information1 “Beer is a passion point for consumers. The strength of the beer category and the continued momentum of our megabrands delivered another quarter of profitable growth. EBITDA increased at the top-end of our outlook and the ongoing optimization of our business drove Underlying EPS growth of 7.1%. The consistent execution of our strategy by our teams and partners drove a solid start to the year and reinforces our confidence in delivering on our outlook for 2025.” – Michel Doukeris, CEO, AB InBev Revenue +1.5% Revenue increased by 1.5% with revenue per hl growth of 3.7%. Reported revenue decreased by 6.3% to 13 628 million USD, impacted by unfavorable currency translation. 4.4% increase in combined revenues of our megabrands, led by Corona, which g
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom